📅 PUBMED DAILY TRIAGE — 2026-07-19

Run: Attempt 3 (repair from attempt-1 salvage) · 2026-07-19T09:30:54Z
Search window: 2026-07-18T00:00:00Z → 2026-07-19T09:30:54Z (CRDT 24 h)
Topics scanned: 9 watchlist + 1 sentinel
Candidates reviewed: 131 across 10 topic queries
Output: 25 articles — 9 HIGH · 16 STANDARD · 0 LOW
Unsolicited finds: 1
Run status: PARTIAL_SUCCESS (candidate PMID lists partially reconstructed from salvage; attempt 2 provider/timeout failure)

🔴🟠 HIGH PRIORITY (score ≥ 8 or EARLY_CANCER_DETECTION / NOVEL_TREATMENT flag)

🩸 Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

[PMID 42470254] Bolarinwa A et al. Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy. Am J Hematol. 2026-07-18. DOI: 10.1002/ajh.70443
Score: 9/10 🟢 | Retrospective cohort · n=545 · Mayo Clinic · 2015–2025
Key finding: KRAS mutation confers HR 8.8 for inferior transplant-censored survival in primary non-CBF AML; post-MPN AML has 0% 5-year survival warranting separate prognostic classification from post-MDS AML. NGS utility is strictly AML-subtype-dependent.
Why it matters: Ten-year multi-institutional cohort; subtype-specific NGS findings are immediately actionable for AML risk stratification and treatment individualization.

[PMID 42471330] Gangat N, Ravandi F. Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms. Blood Cancer J. 2026-07-18. DOI: 10.1038/s41408-026-01578-9
Score: 8/10 🟢 | Expert review · Mayo Clinic + MD Anderson
Key finding: 2026 algorithms endorse venetoclax-based triplets (VEN+HMA+FLT3i/IDH1i) as alternatives to intensive chemotherapy; transplant in first CR for adverse-risk disease; TP53-mutated AML should enter clinical trials.
Why it matters: Authoritative, up-to-date clinical decision framework integrating menin inhibitors and venetoclax combinations; essential reference for the AML watchlist.

🫀 Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

[PMID 42471097] Macías-Cervantes HE et al. Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial. Curr Probl Cardiol. 2026-07-18. DOI: 10.1016/j.cpcardiol.2026.103401
Score: 9/10 🟠 | Double-blind RCT · n=181 · 18-month follow-up · NCT04717986
Key finding: Dapagliflozin 10 mg reduced 18-month HF events from 29.5% (placebo) to 5.3% (active arm) and improved LVEF by 1.56%. ⚠️ CI inconsistency (HR 0.18 vs CI 0.40–0.85) in abstract—likely formatting error; effect direction consistent across all endpoints.
Why it matters: First dedicated RCT confirming SGLT2i benefit specifically in the AMI+T2D overlap population—fills gap left by DAPA-MI (which excluded T2D). Directly actionable pending full-text CI verification.

[PMID 42471184] Song Wen et al. Evidence from two large prospective cohorts: variations in remnant cholesterol inflammation index and the risk of cardiometabolic multimorbidity. Diabetes Res Clin Pract. 2026-07-18. DOI: 10.1016/j.diabres.2026.113448
Score: 8/10 🟢 | Prospective cohort · CHARLS (n=5,870) + ELSA (n=2,295)
Key finding: Novel RCII (remnant cholesterol × hs-CRP/10) predicts cardiometabolic multimorbidity with 14–21% higher risk per ln-unit increase; outperforms either marker alone; stable-high RCII confers highest risk.
Why it matters: Dual-cohort international validation of a clinically deployable composite biomarker integrating lipid + inflammatory risk; directly applicable to integrated CV-metabolic risk stratification.

💊 Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

[PMID 42471483] Grünwald V et al. OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2026-07-18. DOI: 10.1038/s41416-026-03558-z
Score: 8/10 ⬜ | Phase II RCT · n=31 (14 NIVO-IPI; 17 docetaxel)
Key finding: Negative trial. NIVO-IPI showed 0% ORR vs 17.6% for docetaxel; PFS favored docetaxel (1.97 vs 3.66 months, p=0.036); OS numerically inferior with NIVO-IPI (3.97 vs 11.9 months). PD-L1 status had no predictive value.
Why it matters: Critical negative result definitively closing the staggered dual-checkpoint hypothesis in anti-PD-1–refractory SCCHN; shifts salvage treatment back to chemotherapy and redirects future trial design.

[PMID 42470101] Stephan SB et al. (Stephan MT). Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Mol Ther. 2026-07-17. DOI: 10.1016/j.ymthe.2026.07.037
Score: 8/10 🟠 | Preclinical in vivo · Fred Hutch/Baylor
Key finding: A bioinstructive injectable microfoam biomaterial enables bedside or in vivo CAR-T cell programming, bypassing ex vivo manufacturing—a potential paradigm shift in CAR-T accessibility and cost.
Why it matters: Eliminating ex vivo CAR-T manufacturing addresses the most critical access and cost barrier in cell therapy; if this translates to clinic, it could democratize CAR-T therapy globally.

🔬 Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

[PMID 42471313] Gong F et al. (Sun K). Epigenomic modifications define chromatin states to regulate cell-free DNA fragmentomics. Nat Commun. 2026-07-18. DOI: 10.1038/s41467-026-75640-2
Score: 8/10 🔴 | Mechanistic primary research · Nature Communications
Key finding: Chromatin states defined by epigenomic modifications directly regulate cfDNA fragmentation patterns—providing mechanistic grounding for why fragmentomics carries tissue-of-origin cancer signals.
Why it matters: Nature Communications publication providing the biological basis for cfDNA fragmentomics-based cancer detection assays; enables rational design of next-generation liquid biopsy algorithms targeting epigenomic-chromatin fragmentation hotspots.

🧬 Rare Diseases with High Unmet Need

[PMID 42470100] Hou Y et al. Precise hepatic base editing of ASGR1 enables robust and durable LDLR-independent lipid lowering in vivo. Mol Ther. 2026-07-17. DOI: 10.1016/j.ymthe.2026.07.036
Score: 8/10 🟠 | Preclinical in vivo · mouse model
Key finding: Hepatic base editing of ASGR1 achieves robust, durable LDLR-independent lipid lowering in vivo—providing a novel gene therapy approach for homozygous familial hypercholesterolemia and patients unresponsive to statins or PCSK9 inhibitors.
Why it matters: Addresses a critical gap: HoFH patients with no LDLR function are refractory to all current approaches; ASGR1 base editing offers an entirely orthogonal mechanism; published in Molecular Therapy.

[PMID 42470357] Selvasingh JA, Shinn JR. Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment. Otolaryngol Head Neck Surg. 2026-07-18. DOI: 10.1002/ohn.70347
Score: 7/10 🟠 | Perspective/clinical review · gene therapy milestone
Key finding: Otoferlin gene therapy (AAV-OTOF) has demonstrated biological hearing restoration in clinical trials for DFNB9 congenital deafness—the first gene therapy to restore biological hearing in humans.
Why it matters: Contextualizes one of the most significant rare disease gene therapy milestones; DFNB9/otoferlin deafness is the first genetic deafness to be clinically restored; establishes the roadmap for other genetic hearing loss disorders. (HIGH via NOVEL_TREATMENT flag; score 7)

🟢⚪ STANDARD (score 4–7) — Top by Topic

🩸 Hematologic Malignancies

🔬 Early Cancer Detection

🤖 AI/ML in Clinical Diagnostics

🎯 Precision Oncology

💊 Novel Therapeutics

🫀 Cardiovascular-Metabolic

🌿 Aging, Longevity, and Population Health

🧬 Rare Diseases

💡 UNSOLICITED FINDS (Sentinel)

[PMID 42471734] Wang Y et al. Hypoxia tumor-associated macrophages facilitate hepatocellular carcinoma metastasis via uPA-uPAR pathway. J Transl Med. 2026-07-18. DOI: 10.1186/s12967-026-08634-9
Score: 5/10 ⚪ | Translational mechanistic · mixed human/preclinical
Signal: Hypoxia-TAM-uPAR axis as immunotherapy combination target in HCC. Moderate novelty; captured via sentinel scan.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 2
• Treatment Innovation: 8
• Diagnostics: 6
• Drug Development: 6
• Public Health: 1
• Genomics/Precision Medicine: 1
• Other: 1

By evidence maturity:

• Exploratory: 18
• Validated: 6
• Potentially Practice-Changing: 1

By watchlist topic (reviewed / kept / highest score):

Note: 26 topic-article assignments across 25 unique articles (1 article cross-listed in 2 topics counted once in total)

By source type:

• Peer-reviewed: 25 | Preprint: 0

Topics with zero HIGH articles this run:

CBC/ML Hematology (zero hits), AI/ML Clinical Diagnostics, Precision Oncology, Aging/Longevity

🔗 CROSS-TOPIC SIGNALS

• PMID 42471299 — GLP-1 RA + hematologic malignancy risk: novel cross-signal at T1 ∩ T7; scored conservatively (5/10) pending full-text confirmation of association direction
• PMID 42470580 — CHIP + CAR-T: T1 ∩ T6; CHIP-positive myeloma patients have 100% CRS rate (vs 70%); actionable monitoring implication
• PMID 42471718 — Cuproptosis: T6 ∩ T5; copper-targeted therapy as immunotherapy partner
• PMID 42470638 — TTYH3: T8 ∩ T9; lysosomal senescence biology crosses aging and rare lysosomal disease

🔧 RUN NOTES

• Attempt history: Attempt 1 completed with 637 schema validation errors; attempt 2 failed due to provider/timeout; attempt 3 repairs schema from attempt-1 salvage bundle.
• Schema corrections applied: score_breakdown axes corrected from non-standard {novelty_relevance, evidence_maturity} to required {novelty, relevance}; pipeline_priority MEDIUM→STANDARD; classification_confidence moderate→medium; access_level abstract_available→"Abstract only"; evidence_maturity free-text values→schema enum; all required v1.3 article fields added; top-level pipeline_handoff, phase_entry, pipeline_prompt_version added.
• Priority correction: PMID 42470638 (TTYH3, score 7) corrected from HIGH to STANDARD per schema rule (HIGH requires score ≥8 or EARLY_CANCER_DETECTION/NOVEL_TREATMENT flag). PMID 42470357 (otoferlin, score 7) retains HIGH via NOVEL_TREATMENT flag.
• T2 CBC/ML hematology: Both primary and fallback queries returned 0 results in the 24-hour CRDT window. This is an expected low-frequency topic; logged for trending.
• Candidate PMID lists: Partially reconstructed from retained articles only; full 15-candidate lists from original session are unavailable from salvage. coverage_complete=false reflects reconstruction limitation, not a search failure.
• PMID 42471184 authors: Full author list unavailable from salvage; first author Song Wen confirmed via PubMed fetch.
• PMID 42471213 authors: Full author list unavailable from salvage; first author Ziyi Zhou confirmed via PubMed fetch.
• PMID 42471097 CI discrepancy: Abstract reports HR 0.18 with CI 0.40–0.85 (inconsistent); likely abstract formatting error; full-text review recommended before clinical application.

Generated by Pulse/PubMed triage pipeline · attempt 3 of 3 (repair from salvage) · schema v1.3 · 2026-07-19T09:30:54Z